Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment
Status:
Completed
Trial end date:
2019-07-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether the combination of choline alphoscerate 1200mg
per day and nimodipine 90mg per day given orally is more effective than the combination
nimodipine placebo in reducing cognitive decline in patients with subcortical vascular
cognitive impairment